4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. ("4D Molecular" or "the Company") (NASDAQ:FDMT). Investors who purchased 4D Molecular securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FDMT.
4D Molecular Therapeutics Inc Stakeholders Are Welcomed By The Schall Law Firm To Participate In The Securities Fraud Probe
LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
FDMT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. ("4D Molecular" or "the Company") (NASDAQ:FDMT). Investors who purchased 4D Molecular securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FDMT.
The Schall Law Firm Invites FDMT Investors To Join The Securities Fraud Investigation Of 4D Molecular Therapeutics Inc.
LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics, Inc. (FDMT) Special Call Transcript
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT ) Special Call July 17, 2024 6:30 AM ET Company Participants Uneek Mehra - Chief Financial and Business Officer David Kirn - Chief Executive Officer and Co-Founder Robert Kim - Chief Medical Officer Arshad Khanani - Lead Investigator of PRISM Clinical Trial, Sierra Eye Associates Conference Call Participants Salveen Richter - Goldman Sachs Tazeen Ahmad - BofA Securities Jonathan Miller - Evercore ISI Gena Wang - Barclays Clara Dong - Jefferies Operator Ladies and gentlemen, thank you for standing by, and welcome to 4D Molecular Therapeutics Webcast Presentation of Interim Data for 4D 150 24-week Landmark Analysis From PRISM Phase II Population Extension Cohort in Broad Wet AMD. As a reminder, today's call is being recorded.
Investors In FDMT Are Invited To Participate In The Securities Fraud Investigation Of 4D Molecular Therapeutics Inc Conducted By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?
4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
